Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Donna E. Reece, MD, Esther Masih-Khan, PhD, Arooj Khan, Saima Dean, Sharon Fung, Peter Anglin, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 3055.

https://doi.org/10.1182/blood.V116.21.3055.3055

Published: 2010

Journal Articles

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Elizabeth Anderson, Elly Barry, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4155.

https://doi.org/10.1182/blood.V114.22.4155.4155

Published: 2009

Journal Articles

Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference.

Selda Samakoglu, Yelena Usachenko, Tulin Budak-Alpdogan, Santina Acuto, Rosalba DiMarzo, Aurelio Maggio, John Tisdale, Isabelle Riviere, Michel Sadelain

Blood (2005) 106 (11): 1280.

https://doi.org/10.1182/blood.V106.11.1280.1280

Published: 2005

Journal Articles

Treatment with Hydroxyurea in Sickle Cell/ ß Thalassemia: A Long-Term Experience.

Aurelio Maggio, MD, Paolo Rigano, MD, Disma Renda, MD

Blood (2004) 104 (11): 1678.

https://doi.org/10.1182/blood.V104.11.1678.1678

Published: 2004

NARROW

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference.

Treatment with Hydroxyurea in Sickle Cell/ ß Thalassemia: A Long-Term Experience.

Email alerts

ASH Publications

American Society of Hematology

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference.

Treatment with Hydroxyurea in Sickle Cell/ ß Thalassemia: A Long-Term Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only